Study to Assess Switching to B/F/TAF in Treatment Experienced People With HIV Who Are at Least 65 Years of Age
NCT ID: NCT05147740
Last Updated: 2021-12-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
50 participants
INTERVENTIONAL
2021-07-01
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
B/F/TAF
B/F/TAF for 48 weeks
B/F/TAF
50/200/25 mg fixed-dose combination administered orally once daily without regard to food.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
B/F/TAF
50/200/25 mg fixed-dose combination administered orally once daily without regard to food.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Be currently receiving an antiretroviral regimen for ≥ 3 months prior to the screening visit.
3. Have documented plasma HIV-1 RNA \< 50 copies/mL for a minimum of 3 months on current ART regimen.
4. Have a plasma HIV-1 RNA \< 50 copies/mL at screening visit.
Exclusion Criteria
2. Have been treated with B/F/TAF
3. Participants with CrCl \<30 mL/min
4. Known or suspected severe hepatic impairment (Child-Pugh Class C)
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gilead Sciences
INDUSTRY
Tulika Singh, MD
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tulika Singh, MD
Director of Research and Associate Chief Medical Officer
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tulika Singh, MD
Role: PRINCIPAL_INVESTIGATOR
Dap Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
DAP Health
Palm Springs, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Greg Jackson, BS, MBA
Role: primary
Karina Ramirez
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CO-US-38-5713
Identifier Type: -
Identifier Source: org_study_id